Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized trial of HP-5070 for primary palmar hyperhidrosis
jRCT2080224089Phase 2Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxybutynin hydrochloride in Primary hyperhidrosis (PH) (3 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Started Oct 2018; status: completed.
02
Drugs
oxybutynin hydrochloride
03
Conditions
Primary hyperhidrosis (PH)
Beyond the preview
Go deeper on jRCT2080224089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224089.